Recursion Pharmaceuticals Reports Significantly Reduced Q1 Net Loss and Cash Burn, Advances Pipeline
RXRX sits 21% above its 52-week low of $2.8.
Summary
Recursion Pharmaceuticals reported a significantly reduced net loss and lower cash burn in Q1 2026, extending its cash runway, alongside positive clinical pipeline advancements.
Key Events · Earnings and Guidance · RXRX
-
Net Loss Significantly Reduced
Q1 2026 net loss decreased by 42% to $(117.5) million, compared to $(202.5) million in Q1 2025, indicating improved financial performance.
-
Cash Burn Substantially Lowered
Net cash used in operating activities decreased by 38.6% to $(81.1) million in Q1 2026 from $(131.9) million in Q1 2025, extending the company's cash runway.
-
Positive Pipeline Progress Reported
The company announced favorable preliminary safety and pharmacokinetic data for REC-1245 in its Phase 1/2 study, continued momentum for REC-4881 with FDA engagement for a registrational study, and the dosing of the first patient in the REC-4539 Phase 1 clinical study.
-
Material Weaknesses in Internal Controls Persist
Disclosure controls and procedures were deemed ineffective as of March 31, 2026, due to unremediated material weaknesses, though remediation actions are in progress.
Analysis · RXRX · Life Sciences
Recursion Pharmaceuticals' Q1 2026 results demonstrate a substantial improvement in financial efficiency, with net loss significantly reduced by 42% and cash burn from operations decreasing by 38.6% compared to the prior year. This improved cash management extends the company's financial runway, a critical factor for a clinical-stage biotech with an accumulated deficit of $2.2 billion. The company also reported positive clinical progress across its pipeline, including favorable safety data for REC-1245 and the initiation of a Phase 1 study for REC-4539. While revenue declined, the focus for a development-stage company is often on managing expenses and advancing its pipeline, both of which show positive trends. The ongoing material weaknesses in internal controls remain a concern, but remediation efforts are underway. The existing $300 million ATM program, with no shares sold in Q1, provides future capital flexibility without immediate dilution.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.80 to $7.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.